About Emergentec
Emergentec is a company based in Vienna (Austria) founded in 2002. Emergentec offers products and services including OPA i, Computational Vaccinology Platform, Knowledge Graph Platform, Image Analysis Platform, and Digital Drug R&D Platform. Emergentec operates in a competitive market with competitors including Aganitha, Cellumen, PointCross, IOTA Pharma and Growdea Technologies, among others.
- Headquarter Vienna, Austria
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Emergentec Biodevelopment Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.31 M (USD), Grant
Jan 01, 2020
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Emergentec
Emergentec offers a comprehensive portfolio of products and services, including OPA i, Computational Vaccinology Platform, Knowledge Graph Platform, Image Analysis Platform, and Digital Drug R&D Platform.
AI tool for phenotype analysis and personalized treatment predictions.
Platform for vaccine development using data-driven simulations.
System for organizing and analyzing health research data networks.
Software for processing and interpreting medical images.
Platform for in-silico drug positioning and repositioning processes.
Funding Insights of Emergentec
Investors in Emergentec
Emergentec has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Emergentec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emergentec
Investment portfolio details for Emergentec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Emergentec
Detailed financials for Emergentec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emergentec Comparisons
Peer comparison for Emergentec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Emergentec
Emergentec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aganitha, Cellumen, PointCross, IOTA Pharma and Growdea Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-powered drug discovery and development solutions
|
|
| Locked | Locked | Locked |
Systems biology solutions for drug safety and efficacy are provided.
|
|
| Locked | Locked | Locked |
Big data platform & desktop software for preclinical & clinical research & regulatory applications
|
|
| Locked | Locked | Locked |
Offers fragment-based drug discovery products and services.
|
|
| Locked | Locked | Locked |
Offers AI and machine learning for in-silico drug discovery and bioinformatics services.
|
Detailed competitors of Emergentec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emergentec
Complete news archive for Emergentec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emergentec
Emergentec was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Emergentec is headquartered in Vienna, Austria.
emergenTEC, founded by a team of molecular biology and computer science researchers offers products and services for informed decision making in biomarker, target and drug development at all stages - preclinical, clinical and translational. Their software platform e.valuation (which is loaded with data and models, a big data solution) offers integrated workflows for conducting molecular asset evaluation in all stages of drug development. At the clinical stage it helps in deriving biomarker candidate panels for molecular phenotype profilingdrug response measurement, and at the preclinical stage to help in prioritizing on which biomarker, target or drug lead.
Emergentec's top competitors include Aganitha, Cellumen and PointCross.
Emergentec offers OPA i, Computational Vaccinology Platform, Knowledge Graph Platform, Image Analysis Platform, and Digital Drug R&D Platform.
Emergentec has 1 investor. Key investors include European Union.